PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among senior executives at the pharma company to “deliberately slow down&#822… ...

The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the pharmaceutical company.

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the development of the ...

The House Judiciary Committee subpoenaed a former Pfizer Inc. executive, demanding he address allegations of deliberately delaying positive news from the company’s Covid vaccine study until ...